1. Market Research
  2. > Pharmaceutical
  3. > Drug Development Market Trends
  4. > Drug Development Analysis & Statistics 2020 - Japan

Drug Development Analysis & Statistics 2020 - Japan

1-30 of 51 reports

Impetigo - Pipeline Review, H1 2020

  • $ 2000
  • May 2020
  • 45 pages

Impetigo - Pipeline Review, H1 2020 Summary This latest Pharmaceutical and Healthcare disease pipeline guide Impetigo – Pipeline Review, H1 2020, provides an overview of the Impetigo (Infectious Disease) ...

  • Dermatological Condition
  • Drug Development
  • Therapy
  • Japan
  • Ferrer International SA

Gamma-Aminobutyric Acid Receptor Subunit Gamma 2 - Pipeline Review, H1 2020

  • $ 3500
  • April 2020
  • 53 pages

Gamma-Aminobutyric Acid Receptor Subunit Gamma 2 - Pipeline Review, H1 2020 Summary Gamma-Aminobutyric Acid Receptor Subunit Gamma 2 (GABA(A) Receptor Subunit Gamma 2 or GABRG2) pipeline Target constitutes ...

  • Drug Development
  • Pharmaceutical
  • China
  • Japan
  • PAION AG

5-Hydroxytryptamine Receptor 7 - Pipeline Review, H1 2020

  • $ 3500
  • March 2020
  • 74 pages

5-Hydroxytryptamine Receptor 7 - Pipeline Review, H1 2020 Summary 5-Hydroxytryptamine Receptor 7 (5 HT7 or 5 HTX or Serotonin Receptor 7 or HTR7) - 5-HT7 receptor is a member of the GPCR superfamily and ...

  • Drug Development
  • Pharmaceutical
  • Psychotic Disorder
  • Japan
  • Product Initiative

Japan Contract Research Organizations Market: Prospects, Trends Analysis, Market Size and Forecasts up to 2025

  • $ 1500
  • February 2020
  • 40 pages

The country research report on Japan contract research organizations market is a customer intelligence and competitive study of the Japan market. Moreover, the report provides deep insights into demand ...

  • Drug Development
  • Japan
  • Demand
  • Supply

Secondary Hyperparathyroidism - Pipeline Review, H1 2020

  • $ 2000
  • January 2020
  • 61 pages

Secondary Hyperparathyroidism - Pipeline Review, H1 2020 Summary The latest Pharmaceutical and Healthcare disease pipeline guide Secondary Hyperparathyroidism - Pipeline Review, H1 2020, provides an overview ...

  • Drug Development
  • Endocrine Disease
  • Therapy
  • Japan
  • Product Initiative

Hepatocyte Growth Factor - Pipeline Review, H2 2019

  • $ 3500
  • December 2019
  • 76 pages

Hepatocyte Growth Factor - Pipeline Review, H2 2019 Summary Hepatocyte Growth Factor (Hepatopoietin A or Scatter Factor or HGF) pipeline Target constitutes close to 13 molecules. The latest report Hepatocyte ...

  • Drug Development
  • Pharmaceutical
  • Therapy
  • Japan
  • AnGes MG, Inc.

Gamma-Aminobutyric Acid Receptor Subunit Gamma 2 - Pipeline Review, H2 2019

  • $ 3500
  • December 2019
  • 53 pages

Gamma-Aminobutyric Acid Receptor Subunit Gamma 2 - Pipeline Review, H2 2019 Summary According to the recently published report ’Gamma-Aminobutyric Acid Receptor Subunit Gamma 2 - Pipeline Review, H2 ...

  • Drug Development
  • Pharmaceutical
  • Japan
  • United States
  • PAION AG

Impetigo - Pipeline Review, H2 2019

  • $ 2000
  • December 2019
  • 44 pages

Impetigo - Pipeline Review, H2 2019 Summary The latest Pharmaceutical and Healthcare disease pipeline guide Impetigo - Pipeline Review, H2 2019, provides an overview of the Impetigo (Infectious Disease) ...

  • Dermatological Condition
  • Drug Development
  • Therapy
  • Japan
  • Ferrer International SA

Mucopolysaccharidosis II (MPS II) (Hunter Syndrome ) - Pipeline Review, H2 2019

  • $ 2000
  • December 2019
  • 66 pages

Mucopolysaccharidosis II (MPS II) (Hunter Syndrome ) - Pipeline Review, H2 2019 Summary The latest Pharmaceutical and Healthcare disease pipeline guide Mucopolysaccharidosis II (MPS II) (Hunter Syndrome ...

  • Drug Development
  • Endocrine Disease
  • Japan
  • Product Initiative
  • JCR Pharmaceuticals Co., Ltd.

Respiratory Syncytial Virus (RSV): Forecast in Asia-Pacific Markets to 2028

  • $ 8995
  • November 2019
  • 153 pages

Respiratory Syncytial Virus (RSV): Forecast in Asia-Pacific Markets to 2028 Summary Human Respiratory Syncytial Virus (RSV) is an enveloped, single-stranded, negative-sense RNA orthopneumovirus belonging ...

  • Drug Development
  • Japan
  • Demand
  • Forecast
  • RSV LRTI group

Measles Drug pipeline Report 2020- Current Status, Phase, Mechanism, Route of Administration, Companies, and Clinical Trials of Pre-clinical and Clinical Drugs

  • $ 1699
  • October 2019
  • 40 pages

Measles Drug pipeline report- 2020 is an annual R&D review of Measles pipeline candidates. The report presents the current status of all major Measles therapeutic compounds. Detailed insights into Measles ...

  • Clinical Trial
  • Drug Development
  • Japan

Respiratory Syncytial Virus: Opportunity Analysis and Forecasts to 2028

  • $ 10995
  • July 2019
  • 170 pages

Respiratory Syncytial Virus: Opportunity Analysis and Forecasts to 2028 Summary Human respiratory syncytial virus (RSV) is an enveloped, single-stranded, negative-sense RNA orthopneumovirus belonging ...

  • Drug Development
  • Japan
  • Forecast
  • Novavax, Inc.
  • RSV LRTI group

Global High Content Screening (HCS) Industry

  • $ 5600
  • May 2019
  • 194 pages

This report analyzes the worldwide markets for High Content Screening (HCS) in US$ Million. The Global market is further analyzed by the following Segments: Consumables, Instruments, and Others. The ...

  • Drug Development
  • Europe
  • Japan
  • World
  • Company Financials

2019 Japanese Encephalitis Clinical Trials Guide- Companies, Drugs, Phases, Subjects, Current Status and Outlook to 2025

  • $ 1799
  • April 2019
  • 69 pages

The global clinical trial report- “2019 Japanese Encephalitis Clinical Trials Study” provides complete list of trials completed, ongoing and planned for Japanese Encephalitis. It presents in-depth ...

  • Clinical Trial
  • Drug Development
  • Encephalitis
  • Pathology
  • Japan

Chronic Kidney Disease-Mineral Bone Disorders (CKD-MBD): Competitive Landscape to 2027

  • $ 3495
  • March 2019
  • 47 pages

Chronic Kidney Disease-Mineral Bone Disorders (CKD-MBD): Competitive Landscape to 2027 Summary CKD-MBD is an umbrella term used to link renal osteodystrophy with mineral bone disorders and bone pathology ...

  • Drug Development
  • Japan
  • Amgen Inc.
  • Ardelyx, Inc.
  • Kyowa Hakko Kirin Co., Ltd.

2019 Japanese Encephalitis Ongoing Clinical Trials Study- Companies, Countries, Drugs, Phases, Enrollment, Current Status and Markets

  • $ 2199
  • February 2019
  • 40 pages

The ongoing clinical trial research report- “2019 Japanese Encephalitis Ongoing Clinical Trials Study” analyzes the current scenario of all active Japanese Encephalitis trials across the world. The ...

  • Clinical Trial
  • Drug Development
  • Encephalitis
  • Pathology
  • Japan

Glaucoma: Competitive Landscape to 2026

  • $ 3495
  • December 2018
  • 48 pages

Glaucoma: Competitive Landscape to 2026 Summary With no new classes of drugs having been developed for the treatment of glaucoma in the last twenty years, the focus of pharmaceutical companies has begun ...

  • Drug Development
  • Japan
  • Aerie Pharmaceuticals, Inc.
  • Alcon, Inc.
  • Allergan plc

Age-Related Macular Degeneration: Competitive Landscape to 2026

  • $ 3495
  • December 2018
  • 153 pages

Age-Related Macular Degeneration: Competitive Landscape to 2026 Summary The Age-Related Macular Degeneration (AMD) market has been dominated by big pharma companies and their pipeline candidates are ensuring ...

  • Drug Development
  • Japan
  • Novartis AG
  • Regeneron Pharmaceuticals, Inc.
  • Roche Group

TransGenic Inc (2342) - Pharmaceuticals & Healthcare - Deals and Alliances Profile

  • $ 250
  • December 2018
  • 28 pages

Summary TransGenic Inc (TransGenic) is a biotechnology company which develops and distributes genetically engineered animals and antibodies and licensing of these activities.The products and services of ...

  • Drug Development
  • Pharmaceutical
  • Japan
  • Company
  • TransGenic, Inc.

3-D Matrix Ltd (7777) - Product Pipeline Analysis, 2018 Update

  • $ 750
  • November 2018
  • 32 pages

Summary 3-D Matrix Ltd (3-D Matrix) is a regenerative medicine company that focuses at commercializing its self-assembling peptide technology. It develops medical products by applying this technology unde ...

  • Drug Development
  • Australia
  • Japan
  • Company
  • 3-D Matrix, Inc.

JCR Pharmaceuticals Co Ltd (4552) - Pharmaceuticals & Healthcare - Deals and Alliances Profile

  • $ 250
  • November 2018
  • 30 pages

Summary JCR Pharmaceuticals Co Ltd (JCR) manufactures, sells, buys, imports and exports pharmaceutical products.It provides biopharmaceuticals in the field of regenerative medicine for the treatment of ...

  • Drug Development
  • Pharmaceutical
  • Japan
  • Trade
  • JCR Pharmaceuticals Co., Ltd.

NovAliX SAS - Pharmaceuticals & Healthcare - Deals and Alliances Profile

  • $ 250
  • November 2018
  • 20 pages

Summary NovAliX SAS (NovAliX) is a contract research organization that offers outsourcing and insourcing research services for drug discovery.The organization provides chemical biology services such as ...

  • Drug Development
  • Pharmaceutical
  • France
  • Japan
  • Company Operations

Allergies Global Clinical Trials Review, H2, 2018

  • $ 2500
  • October 2018
  • 567 pages

Allergies Global Clinical Trials Review, H2, 2018 Summary GlobalData’s clinical trial report, “Allergies Global Clinical Trials Review, H2, 2018" provides an overview of Allergies clinical trials ...

  • Allergy
  • Clinical Trial
  • Drug Development
  • Pharmaceutical
  • Japan

Glucosylceramidase (Acid Beta Glucosidase or Alglucerase or D Glucosyl N Acylsphingosine Glucohydrolase or Beta Glucocerebrosidase or Imiglucerase or GBA or EC 3.2.1.45) - Pipeline Review, H2 2018

  • $ 3500
  • October 2018
  • 62 pages

Glucosylceramidase (Acid Beta Glucosidase or Alglucerase or D Glucosyl N Acylsphingosine Glucohydrolase or Beta Glucocerebrosidase or Imiglucerase or GBA or EC 3.2.1.45) - Pipeline Review, H2 2018 Su ...

  • Drug Development
  • Psychotic Disorder
  • Therapy
  • Japan
  • Protalix BioTherapeutics, Inc.

Sosei Group Corp (4565) - Pharmaceuticals & Healthcare - Deals and Alliances Profile

  • $ 250
  • October 2018
  • 64 pages

Summary Sosei Group Corp (Sosei) is a biopharmaceutical company that develops and commercializes drugs.The company’s pipeline products include NorLevo, NVA237, QVA149 and SO-1105. Its NorLevo product ...

  • Drug Development
  • Therapy
  • Japan
  • Company
  • Sosei Group Corporation

CMIC Holdings Co Ltd (2309) - Pharmaceuticals & Healthcare - Deals and Alliances Profile

  • $ 250
  • October 2018
  • 39 pages

Summary CMIC Holdings Co Ltd (CMIC) is a contract research organization that supports drug development services.The organization offers medical research related services to pharmaceuticals and medical ...

  • Drug Development
  • Japan
  • Deals & Alliance
  • M&A
  • CMIC Holdings Co Ltd

Transmembrane Prolyl 4 Hydroxylase (Hypoxia Inducible Factor Prolyl Hydroxylase 4 or P4HTM or EC 1.14.11.) - Pipeline Review, H2 2018

  • $ 3500
  • September 2018
  • 62 pages

Transmembrane Prolyl 4 Hydroxylase (Hypoxia Inducible Factor Prolyl Hydroxylase 4 or P4HTM or EC 1.14.11.) - Pipeline Review, H2 2018 Summary According to the recently published report ’Transmembrane ...

  • Blood Disease
  • Drug Development
  • Therapy
  • Japan
  • FibroGen, Inc.

JRI Orthopaedics Ltd - Product Pipeline Analysis, 2018 Update

  • $ 750
  • September 2018
  • 51 pages

Summary JRI Orthopaedics Ltd (JRI) a subsidiary of Orthopaedic Research UK (ORUK), is a manufacturer of orthopaedic implants and surgical instruments.The company develops products for joint replacement, ...

  • Clinical Trial
  • Drug Development
  • Orthopedics
  • Japan
  • JRI Orthopaedics Limited

Axial Spondyloarthritis (AxSpA): Competitive Landscape to 2026

  • $ 3495
  • June 2018
  • 52 pages

Axial Spondyloarthritis (AxSpA): Competitive Landscape to 2026 Summary Axial Spondyloarthritis (AxSpA) is a chronic, immune-mediated inflammatory disease of the axial skeleton (sacroiliac joints and spine). ...

  • Drug Development
  • Japan
  • AbbVie Inc.
  • Eli Lilly & Co.
  • Novartis AG

Pollen Allergy Global Clinical Trials Review, H1, 2018

  • $ 2500
  • May 2018
  • 216 pages

Pollen Allergy Global Clinical Trials Review, H1, 2018 Summary GlobalData’s clinical trial report, “Pollen Allergy Global Clinical Trials Review, H1, 2018" provides an overview of Pollen Allergy clinical ...

  • Clinical Trial
  • Drug Development
  • Pharmaceutical
  • Japan
  • Allergy Therapeutics plc

Reportlinker.com © Copyright 2020. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.

Make sure you don’t miss any news and follow us on